Inhalations Sciences: US patent on XposeALI extended until 2034
(Stockholm October 25, 2021) Inhalation Sciences’ US patent protection on its in vitro Cell Culturing module XposeALI® has been extended until 2034. CEO Manoush Masarrat: “The US is a major market with enormous potential. XposeALI® offers US developers of inhaled pharmaceuticals an important competitive advantage.”
ISAB’s first US patent application was submitted on September 25th, 2013, when it was approved up until December 1st, 2020 under the number 11054414. The patent has now been extended and is valid until 2034.
ISAB’s XposeALI® is a highly innovative and leading instrument within in vitro cell culturing that combines aerosol capability with 3D cell models cultured in an Air Liquid Interface. On October 12th, ISAB announced that XposeALI® will be used to test a Mars dust surrogate for the European Space Agency in a research project with the Institute for Environmental Medicine (IMM) at Karolinska Institutet (KI) in Stockholm, Sweden.
ISAB CEO Manoush Masarrat: “The US is a major market with enormous potential. The outstanding capabilities and precision of XposeALI® offers developers of inhaled pharmaceuticals in the US exceptional precision, reduced risk and a major competitive advantage throughout coming decades.”
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
Tags: